E-47 | 5 -Year Chronic Limb Ischemia Outcomes for Peripheral Artery Disease Patients with Type 2 Diabetes and Obesity on Semaglutide vs Liraglutide: A Propensity Score Matched Analysis

View Full Paper

Ask AI

Bookmark

Share

Key Points

This study aims to evaluate the long-term outcomes of semaglutide versus liraglutide in patients with chronic limb ischemia due to peripheral artery disease and type 2 diabetes.
Propensity score matched analysis of patients receiving semaglutide or liraglutide
Assessment of key outcomes like composite efficacy events, restenosis, and CD-TLR over 5 years
Analysis stratified by sex to identify differences in treatment effects and outcomes.
Composite efficacy events at 1 year were significantly lower in the semaglutide group compared to liraglutide (females: 23.5% vs. 57.1%, p=0.0078; males: 26.5% vs. 56.0%, p=0.0006)
At 2 years, the benefit persisted with lower rates for the semaglutide group (females: 34.1% vs. 68.4%, p=0.0160; males: 40.7% vs. 66.7%, p=0.0060)
DRS demonstrated lower binary restenosis and CD-TLR rates across both sexes, while highlighting the need for sex-specific strategies.

Compares outcomes of semaglutide and liraglutide in peripheral artery disease patients, suggesting tailored therapies are needed.

No abstract yet. The journal hasn't published one we can show.

No takes yet. Share an insight, caveat, or question.

Dele et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share